Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Encorafenib + binimetinib standard-dose vs high-dose in BRAFV600-mutant melanoma brain metastasis
2018-004555-21Phase 2Completed
- Sponsor
- Array BioPharma
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of encorafenib and binimetinib in melanoma (2 arms), sponsored by Array BioPharma. Primary endpoint: Safety Lead-In. Started Apr 2019; status: completed.
02
Drugs
encorafenibbinimetinib
03
Conditions
melanoma
Beyond the preview
Go deeper on 2018-004555-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004555-21.